Notice of Intent to Sole Source Reagents, calibrators and controls to be used in conjunction with the VITROS 3600 Immunodiagnostic system, manufactured by QuidelOrtho Sales Company, LLC

The Centers for Disease Control and Prevention (CDC) is issuing a notice of intent to sole source the acquisition of reagents, calibrators, and controls to be used in conjunction with the VITROS 3600 Immunodiagnostic system, manufactured by QuidelOrtho Sales Company, LLC. The sole source justification is based on the fact that the VITROS 3600 system is FDA-approved and highly reliable, and it is imperative to continue using the methods offered by the VITROS platform consistently as long as it remains available in the US. The CDC is seeking expressions of interest from potential offerors, but it is unlikely that other sources will be considered. The project involves the acquisition of reagents, calibrators, and controls for the VITROS 3600 system, which will be used for hepatitis B and C serosurvey for 5000 specimens from Mozambique. • The VITROS 3600 system is FDA-approved and highly reliable. • The system is used for hepatitis B and C serosurvey. • The CDC is seeking expressions of interest from potential offerors. • The project involves the acquisition of reagents, calibrators, and controls for the VITROS 3600 system. • The estimated procurement amount is $97,229.54.